Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7707 results

  1. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  2. Atrial fibrillation - ximelagatran [ID376]

    Discontinued [GID-TAG377]

    Technology appraisal guidance
    Discontinued

  3. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued [GID-TA11005]

    Technology appraisal guidance
    Discontinued

  6. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued [GID-TA11399]

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued [GID-TA11421]

    Technology appraisal guidance
    Discontinued

  8. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued [GID-TA10316]

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued [GID-TA11024]

    Technology appraisal guidance
    Discontinued

  10. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE interventional procedures guidance 796.

    Interventional procedures guidance
    Published
    28 February 2018

  12. Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)

    This guidance has been updated and replaced by NICE health technology evaluation 19.

    Medtech innovation briefing
    Published
    5 July 2022

  13. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    This guidance has been updated and replaced by NICE health technology evaluation 19, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE health technology evaluation 18, which covers using myCOPD for pulmonary rehabilitation.

    Medical technologies guidance
    Published
    31 March 2022

  14. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development [GID-TA11582] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development